Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

In-cell Redox Catalysis by Co(III) Metallodrugs as New Tools for Cancer Treatments

Project description

Pioneering a paradigm shift in cancer therapy through innovative catalysis

As cancer continues to challenge medical boundaries, the quest for more effective and less invasive treatments intensifies. Traditional therapies often fall short, prompting a search for novel solutions. With the support of Marie Skłodowska-Curie Actions, the Co-CaReD project aims to reshape cancer treatment by harnessing the power of in-cell redox catalysis. By designing cutting-edge catalytic systems based on cost-effective and biocompatible cobalt, Co-CaReD aims to create a new frontier of therapies, offering hope for safer and more accessible options in the fight against cancer. Unlike its counterparts, cobalt boasts unique chemical properties that pave the way for unparalleled reactivity pathways and drug candidates that are more affordable and less toxic.

Objective

The search of new therapies for cancer is a primary EU mission. In-cell redox catalysis promoted by organometallic complexes of precious metals as Ru(II), Os(II), Rh(III) and Ir(III) is a novel promising concept to access more efficient, safer, and less invasive medicines.
Co-CaReD aims to design new in-cell catalytic systems based on half-sandwich Co(III) complexes. Cobalt combines effective catalytic performances for biomedical applications and high catalytic versatility. Moreover, it is a cheap, sustainable, and biocompatible metal whose peculiar chemical properties can access unique reactivity pathways. The project will focus on the development of new synthetic catalysts, on their applications in redox reactions of therapeutic interest, involving known examples and unprecedent cases of study, and on the unveiling of their biological mechanism of action in cancer cells.
Co-CaReD will be implemented in a vibrant and stimulating research environment at IMDEA Nanociencia, in Dr. Ana Pizarro research group. The project will benefit of the complementary expertise of the ER in organometallic chemistry and redox catalysis and of the supervisor in studying the intracellular reactivity at the molecular level of metal-based drugs. An intense training plan is designed to equip the researcher with the necessary skills to study the biological activity of the Co(III) catalysts – including single-cell studies – and to design proof-of-concept experiments that confirm the occurrence of a metal-based catalytic reactivity inside the human cells.
The main goal of Co-CaReD is to generate novel redox catalytic systems based on more biocompatible, less toxic, and cheaper cobalt drug candidates, as complementary tools to noble metal complexes.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-PF-01

See all projects funded under this call

Coordinator

FUNDACION IMDEA NANOCIENCIA
Net EU contribution
€ 165 312,96
Address
CALLE FARADAY 9 CIUDAD UNIVERSITARIA DE CANTOBLANCO
28049 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
No data